Aren't you amazed about how fast the world has come together to find a collective solution for COVID-19? We have learned in the past months that we can compress the traditional vaccine paradigm, which is between 5 to 10 years to just 4 to 18 months.
The tremendous impact of the COVID crisis has significantly raised the global expectations and appreciation for innovation, digital, and excellence, which leads us to the question: what will the new normal be?
That's why there has never been a better time to connect, even virtually, in order to shape the transformation of the pharmaceutical industry with knowledge and expertise across the entire lifecycle.
Join us at the 2020 ISPE Biotechnology Virtual Conference on 7–8 October to hear from the experts as they discuss:
Your event experience includes access to two ATMP-focused workshops where you will discuss, debate, and identify potential deliverables.
Included in your conference registration are exclusive facilities tour of Produlab Pharma (PP), Catalent, and Takeda.
Designed to be highly interactive and hosted on a state-of-the-art digital platform, the 2020 ISPE Biotechnology Virtual Conference delivers the same high-quality content and premier engagement opportunities that you expect from this signature ISPE event.
I truly believe you and your team will find this event invaluable based on the opportunity for regulatory duty and comprehensive agenda addressing timely, industry-critical topics.
In addition, we are pleased to announce pricing for the 2020 ISPE Biotechnology Virtual Conference ranging from € 35 to € 495.
I look forward to seeing you there also for virtual networking!
At the 2024 ISPE Annual Meeting & Expo held in Orlando, Florida, USA, in October, a panel of global regulators and industry professionals addressed harmonization and regulatory convergence, digitalization, particularly the use of artificial intelligence (AI), and supply chain resilience.
At the 2024 ISPE Annual Meeting & Expo, held 13-16 October in Orlando, Florida, USA Nina Cauchon, PhD, Director, Regulatory Affairs -- CMC, Amgen, led a session on the global adoption status and implementation strategies for recent International Council on Harmonization (ICH) guidelines
Theresa Mullin, PhD, Associate Director for Strategic Initiatives at the US Food and Drug Administration’s (US FDA) Center for Drug Evaluation and Research (CDER), opened the 2024 ISPE Meeting & Expo in...